You are being asked to participate in this research study because you are an HIV-positive patient with an incurable cancer for which no standard therapy is available or you were diagnosed with Hodgkin lymphoma and it came back after standard therapy (relapsed). You may have already been treated with chemotherapy, radiation therapy or other treatments, and your disease is now growing. Your participation is voluntary, which means you can choose whether or not you want to participate.
The main purpose of this study is to first test the safety of giving nivolumab alone and then in combination with ipilimumab in HIV-positive people with incurable cancers or relapsed Hodgkin lymphoma. We would also like to find out what effects, good and/or bad, this combination of drugs may have on your cancer. The FDA approved nivolumab to treat melanoma, non-small cell lung cancer, and Hodgkin lymphoma and approved ipilimumab to treat advanced melanoma. The combination of nivolumab and ipilimumab is considered to be investigational because it is not approved for use with your type of cancer.
If you meet all of the criteria for being in the study, you will be registered to participate.
Most of the procedures you will have are part of the usual approach for your cancer. However, there are some extra procedures that you will need to have if you take part in this study.
Study Identifier: AMC-095
Contact the research team to learn more about this study.